Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study
Article
[키워드] adjuvant treatment
age
alterations
Anti-inflammatory
antioxidant
appear
Asymptomatic
baseline
Biomarkers
BMI
cascade
coagulative
Control
control group
controls
Coronavirus disease 2019
COVID-19
CRP
Cytokines storm
D-dimer level
demonstrated
diagnosis of COVID-19
dose
early stage
Effect
enrolled
exhibited
Gender
homogeneous
IgG
IL-6
Inflammation
Inflammatory
inflammatory state
Laboratory parameters
long COVID syndrome
lymphocyte
neutrophil
oral food supplement
oxidative stress
palmitoylethanolamide
Patient
Randomized
randomized clinical trial
reduction in
reductions in
SARS-CoV-2
serological response
significant decrease
significant increase
subpopulation
treated
Treatment
two groups
um-PEA
[DOI] 10.3390/ph15020253 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/ph15020253 PMC 바로가기 [Article Type] Article